MARKET

XNCR

XNCR

Xencor
NASDAQ
15.17
-0.05
-0.33%
Opening 11:59 12/29 EST
OPEN
15.08
PREV CLOSE
15.22
HIGH
15.41
LOW
14.93
VOLUME
102.57K
TURNOVER
--
52 WEEK HIGH
24.94
52 WEEK LOW
6.92
MARKET CAP
1.08B
P/E (TTM)
-8.0542
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XNCR last week (1222-1226)?
Weekly Report · 8h ago
Top Xencor Insiders Quietly Cash Out in Major Stock Moves
TipRanks · 5d ago
Xencor SVP & CSO John R. Desjarlais Reports Disposal of Common Shares
Reuters · 5d ago
Weekly Report: what happened at XNCR last week (1215-1219)?
Weekly Report · 12/22 09:05
Xencor Is Maintained at Overweight by Barclays
Dow Jones · 12/17 18:11
Barclays Maintains Overweight on Xencor, Raises Price Target to $26
Benzinga · 12/17 18:01
Incyte announces EU approval of Xencor-partnered lymphoma therapy
Seeking Alpha · 12/17 16:52
Xencor price target raised to $26 from $23 at Barclays
TipRanks · 12/17 11:00
More
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Webull offers Xencor Inc stock information, including NASDAQ: XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.